Analysis of clinical decision-making in multi-disciplinary cancer teams

被引:186
作者
Blazeby, JM
Wilson, L
Metcalfe, C
Nicklin, J
English, R
Donovan, JL
机构
[1] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England
[2] Univ Bristol, Clin Sci S Bristol, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
decisions; co-morbid health; multi-disciplinary teams; patient choice;
D O I
10.1093/annonc/mdj102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Management decisions for patients with cancer are frequently taken within the context of a multi-disciplinary team (MDT). There is little known, however, about decision-making at team meetings and whether MDT decisions are all implemented. This study evaluated team decision-making in upper gastrointestinal cancer. Consecutive MDT treatment decisions were recorded for patients with oesophageal, gastric, pancreatic and peri-ampullary tumours. Implementation of MDT decisions was investigated by examining hospital records. Where decisions were implemented it was recorded as concordant and discordant if the decision changed. Reasons for changes in MDT decisions were identified. 273 decisions were studied and 41 (15.1%) were discordant (not implemented), (95% confidence interval 11.1-20.0%). Looking at the reasons for discordance, 18 (43.9%) were due to co-morbid health issues, 14 (34.2%) related to patient choice and 8 (19.5%) decisions changed when more clinical information was available. For one discordant decision, the reason was not apparent. Discordant decisions were more frequent for patients with pancreatic or gastric carcinoma as compared to oesophageal cancer (P = 0.001). Results show that monitoring concordance between MDT decisions and final treatment implementation is useful to inform team decision-making. For upper gastrointestinal cancer, MDTs require more information about co morbid disease and patient choice to truly optimize the implementation of multi-disciplinary expertise.
引用
收藏
页码:457 / 460
页数:4
相关论文
共 15 条
[1]  
Allum WH, 2002, GUT, V50, P1
[2]  
[Anonymous], 1999, J Regist Manag
[3]  
Bartels H, 1998, BRIT J SURG, V85, P840
[4]  
Borrill C.S., 2000, BRIT J HLTH CARE MAN, V6, P364, DOI DOI 10.12968/BJHC.2000.6.8.19300
[5]  
*EX NHS, 2001, IMPR OUTC UPP GASTR
[6]   Using service guidance to shape the delivery of cancer services: experience in the UK [J].
Haward, RA .
BRITISH JOURNAL OF CANCER, 2003, 89 (Suppl 1) :S12-S14
[7]   Review of determinants of patients preferences for adjuvant therapy in cancer [J].
Jansen, SJT ;
Otten, W ;
Stiggelbout, AM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3181-3190
[8]  
McCulloch P, 2003, BMJ-BRIT MED J, V327, P756
[9]  
NHS, 2000, NHS CANC PLAN
[10]   Development of a new head and neck cancer-specific comorbidity index [J].
Piccirillo, JF ;
Lacy, PD ;
Basu, A ;
Spitznagel, EL .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2002, 128 (10) :1172-1179